O3-4 First-line tislelizumab plus chemotherapy in gastric/gastroesophageal junction cancer: RATIONALE-305 Asian Subgroup

IF 56.7 1区医学 Q1 ONCOLOGY

Annals of Oncology Pub Date : 2024-10-01 DOI:10.1016/j.annonc.2024.07.636

K. Kato , Y. Bai , J. Shi , K. Lee , J. Wang , H. Pan , S. Rha , R. Zhang , H. Hirano , K. Yamaguchi , Z. Guo , Y. Ba , L. Yang , H. Tsukuda , Y. Xu , T. Sheng , S. Yang , L. Li , D. Oh , R. Xu

引用次数: 0

查看原文本刊更多论文

O3-4 胃癌/胃食管交界处癌一线替赛珠单抗联合化疗：RATIONALE-305 亚洲亚组

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of Oncology 医学-肿瘤学

CiteScore

63.90

自引率

1.00%

发文量

3712

审稿时长

2-3 weeks

期刊介绍： Annals of Oncology, the official journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology, offers rapid and efficient peer-reviewed publications on innovative cancer treatments and translational research in oncology and precision medicine. The journal primarily focuses on areas such as systemic anticancer therapy, with a specific emphasis on molecular targeted agents and new immune therapies. We also welcome randomized trials, including negative results, as well as top-level guidelines. Additionally, we encourage submissions in emerging fields that are crucial to personalized medicine, such as molecular pathology, bioinformatics, modern statistics, and biotechnologies. Manuscripts related to radiotherapy, surgery, and pediatrics will be considered if they demonstrate a clear interaction with any of the aforementioned fields or if they present groundbreaking findings. Our international editorial board comprises renowned experts who are leaders in their respective fields. Through Annals of Oncology, we strive to provide the most effective communication on the dynamic and ever-evolving global oncology landscape.